Type your tag names separated by a space and hit enter

Eradication of Haemophilus influenzae type b disease in southern California. Kaiser-UCLA Vaccine Study Group.

Abstract

OBJECTIVE

To assess the effects of Haemophilus influenzae vaccination of infants.

RESEARCH DESIGN

We evaluated H influenzae type b (Hib) disease rates in Los Angeles County, California (population, 9 million; 1983 through 1992), and in the Southern California Kaiser Health Plan (2.5 million enrollees; 1988 through 1992) during the past decade. Cases were obtained through active and passive disease surveillance in the two populations. The following vaccines were used during the study period (1983 through 1992): (1) Hib polysaccharide vaccine (polyribosyl ribitol phosphate) (used from 1985 through 1987 for children 24 through 60 months of age); (2) Hib polysaccharide-diphtheria toxoid conjugate, Hib polysaccharide CRM197 mutant diphtheria toxoid conjugate vaccine, and Hib polysaccharide outer-membrane protein of group B meningococcus conjugate vaccine in older children (1988 through 1990; ages 15 through 60 months); and (3) Hib polysaccharide CRM197 mutant diphtheria toxoid conjugate vaccine and Hib polysaccharide outer-membrane protein of group B meningococcus conjugate vaccine used in infants (1991 through 1992).

MEASUREMENTS AND RESULTS

Between 1983 and 1988, the Hib disease incidence in Los Angeles County was unchanged (32.7 to 42.5/100,000 person-years in children younger than 5 years). In 1989 through 1990, before Hib conjugate licensure for infant use, Hib disease rates in all age groups declined. After licensure of Hib vaccines for infants in 1990, there was a further fivefold decrease in infants. More dramatic decreases occurred in the better-immunized Kaiser Health Plan children aged 0 through 60 months (53 cases in 1989, only two cases in 1992).

CONCLUSIONS

The Hib disease has been nearly eradicated in a fully immunized population (Kaiser Health Plan), and significant reductions have also occurred in Los Angeles County.

Links

  • Publisher Full Text
  • Authors+Show Affiliations

    ,

    UCLA Center for Vaccine Research, Research and Education Institute, Harbor-UCLA Medical Center, Torrance.

    , , , , ,

    Source

    MeSH

    California
    Child, Preschool
    Haemophilus Infections
    Haemophilus Vaccines
    Haemophilus influenzae
    Humans
    Incidence
    Infant
    Infant, Newborn
    Vaccination

    Pub Type(s)

    Journal Article
    Research Support, Non-U.S. Gov't
    Research Support, U.S. Gov't, P.H.S.

    Language

    eng

    PubMed ID

    8143010

    Citation

    Vadheim, C M., et al. "Eradication of Haemophilus Influenzae Type B Disease in Southern California. Kaiser-UCLA Vaccine Study Group." Archives of Pediatrics & Adolescent Medicine, vol. 148, no. 1, 1994, pp. 51-6.
    Vadheim CM, Greenberg DP, Eriksen E, et al. Eradication of Haemophilus influenzae type b disease in southern California. Kaiser-UCLA Vaccine Study Group. Arch Pediatr Adolesc Med. 1994;148(1):51-6.
    Vadheim, C. M., Greenberg, D. P., Eriksen, E., Hemenway, L., Bendana, N., Mascola, L., & Ward, J. I. (1994). Eradication of Haemophilus influenzae type b disease in southern California. Kaiser-UCLA Vaccine Study Group. Archives of Pediatrics & Adolescent Medicine, 148(1), pp. 51-6.
    Vadheim CM, et al. Eradication of Haemophilus Influenzae Type B Disease in Southern California. Kaiser-UCLA Vaccine Study Group. Arch Pediatr Adolesc Med. 1994;148(1):51-6. PubMed PMID: 8143010.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - Eradication of Haemophilus influenzae type b disease in southern California. Kaiser-UCLA Vaccine Study Group. AU - Vadheim,C M, AU - Greenberg,D P, AU - Eriksen,E, AU - Hemenway,L, AU - Bendana,N, AU - Mascola,L, AU - Ward,J I, PY - 1994/1/1/pubmed PY - 1994/1/1/medline PY - 1994/1/1/entrez SP - 51 EP - 6 JF - Archives of pediatrics & adolescent medicine JO - Arch Pediatr Adolesc Med VL - 148 IS - 1 N2 - OBJECTIVE: To assess the effects of Haemophilus influenzae vaccination of infants. RESEARCH DESIGN: We evaluated H influenzae type b (Hib) disease rates in Los Angeles County, California (population, 9 million; 1983 through 1992), and in the Southern California Kaiser Health Plan (2.5 million enrollees; 1988 through 1992) during the past decade. Cases were obtained through active and passive disease surveillance in the two populations. The following vaccines were used during the study period (1983 through 1992): (1) Hib polysaccharide vaccine (polyribosyl ribitol phosphate) (used from 1985 through 1987 for children 24 through 60 months of age); (2) Hib polysaccharide-diphtheria toxoid conjugate, Hib polysaccharide CRM197 mutant diphtheria toxoid conjugate vaccine, and Hib polysaccharide outer-membrane protein of group B meningococcus conjugate vaccine in older children (1988 through 1990; ages 15 through 60 months); and (3) Hib polysaccharide CRM197 mutant diphtheria toxoid conjugate vaccine and Hib polysaccharide outer-membrane protein of group B meningococcus conjugate vaccine used in infants (1991 through 1992). MEASUREMENTS AND RESULTS: Between 1983 and 1988, the Hib disease incidence in Los Angeles County was unchanged (32.7 to 42.5/100,000 person-years in children younger than 5 years). In 1989 through 1990, before Hib conjugate licensure for infant use, Hib disease rates in all age groups declined. After licensure of Hib vaccines for infants in 1990, there was a further fivefold decrease in infants. More dramatic decreases occurred in the better-immunized Kaiser Health Plan children aged 0 through 60 months (53 cases in 1989, only two cases in 1992). CONCLUSIONS: The Hib disease has been nearly eradicated in a fully immunized population (Kaiser Health Plan), and significant reductions have also occurred in Los Angeles County. SN - 1072-4710 UR - https://www.unboundmedicine.com/medline/citation/8143010/Eradication_of_Haemophilus_influenzae_type_b_disease_in_southern_California__Kaiser_UCLA_Vaccine_Study_Group_ L2 - https://jamanetwork.com/journals/jamapediatrics/fullarticle/vol/148/pg/51 DB - PRIME DP - Unbound Medicine ER -